HFCAS OpenIR  > 中科院强磁场科学中心
Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia
Liu, Xuesong1,2; Wang, Beilei1,2; Chen, Cheng1,2; Jiang, Zongru1,2; Hu, Chen1,2; Wu, Hong1; Zhang, Yicong1,2; Liu, Xiaochuan1; Wang, Wenliang1,2; Wang, Junjie1,2; Hu, Zhenquan1; Wang, Aoli1; Huang, Tao3,4; Liu, Qingwang3,4; Wang, Wei1,4; Wang, Li1,2; Wang, Wenchao1,4; Ren, Tao3,4; Li, Lili5; Xia, Ruixiang5; Ge, Jian5; Liu, Qingsong1,2,3,4,6; Liu, Jing1,4
2018-12-05
Source PublicationEUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
ISSN0223-5234
Volume160Pages:61-81
Corresponding AuthorGe, Jian(gejian@ahmu.edu.cn) ; Liu, Qingsong(qsliu97@hmfl.ac.cn) ; Liu, Jing(jingliu@hmfl.ac.cn)
AbstractThere is still a great demand in the clinic for the drugs which can overcome a variety of imatinib resistant ABL mutants. Starting from a type I inhibitor axitinib, which has been reported to overcome ABL-T3151 mutant induced resistance, through a structure guided drug design approach and binding mode switch strategy, we have discovered a novel type II ABL inhibitor 24 (CHMFL-ABL-121), which significantly improved the inhibitory activity against ABL wt and a broad spectrum of mutants including the most prevalent imatinib-resistant gatekeeper mutant 13151. 24 exhibited IC50 values of 2 nM and 0.2 nM against purified inactive ABL wt and 13151 kinase protein respectively and inhibited the proliferation of the established CML cell lines with GI(50) at single digit nM. In cellular context, 24 strongly affected BCR-ABL mediated signaling pathways and induced apoptosis as well as arrested cell cycle at G0/G1 phase. In the in vivo study, 50 mg/kg/day dosage of 24 displayed TGI of 52% in the TEL-ABLT315I-BaF3 cell inoculated allograft mouse model without obvious toxicity. (C) 2018 Elsevier Masson SAS. All rights reserved.
KeywordABL kinase Kinase inhibitor ABL mutant CML
Funding OrganizationNational Natural Science Foundation of China ; National Natural Science Foundation of China ; National Natural Science Foundation of China ; National Natural Science Foundation of China ; National Key Research and Development Program of China ; National Key Research and Development Program of China ; National Key Research and Development Program of China ; National Key Research and Development Program of China ; Major Science and Technology Program of Anhui Province ; Major Science and Technology Program of Anhui Province ; Major Science and Technology Program of Anhui Province ; Major Science and Technology Program of Anhui Province ; Natural Science Foundation of Anhui Province ; Natural Science Foundation of Anhui Province ; Natural Science Foundation of Anhui Province ; Natural Science Foundation of Anhui Province ; Natural Science Foundation of the Anhui Higher Education Institutions of China ; Natural Science Foundation of the Anhui Higher Education Institutions of China ; Natural Science Foundation of the Anhui Higher Education Institutions of China ; Natural Science Foundation of the Anhui Higher Education Institutions of China ; Frontier Science Key Research Program of CAS ; Frontier Science Key Research Program of CAS ; Frontier Science Key Research Program of CAS ; Frontier Science Key Research Program of CAS ; National Natural Science Foundation of China ; National Natural Science Foundation of China ; National Natural Science Foundation of China ; National Natural Science Foundation of China ; National Key Research and Development Program of China ; National Key Research and Development Program of China ; National Key Research and Development Program of China ; National Key Research and Development Program of China ; Major Science and Technology Program of Anhui Province ; Major Science and Technology Program of Anhui Province ; Major Science and Technology Program of Anhui Province ; Major Science and Technology Program of Anhui Province ; Natural Science Foundation of Anhui Province ; Natural Science Foundation of Anhui Province ; Natural Science Foundation of Anhui Province ; Natural Science Foundation of Anhui Province ; Natural Science Foundation of the Anhui Higher Education Institutions of China ; Natural Science Foundation of the Anhui Higher Education Institutions of China ; Natural Science Foundation of the Anhui Higher Education Institutions of China ; Natural Science Foundation of the Anhui Higher Education Institutions of China ; Frontier Science Key Research Program of CAS ; Frontier Science Key Research Program of CAS ; Frontier Science Key Research Program of CAS ; Frontier Science Key Research Program of CAS ; National Natural Science Foundation of China ; National Natural Science Foundation of China ; National Natural Science Foundation of China ; National Natural Science Foundation of China ; National Key Research and Development Program of China ; National Key Research and Development Program of China ; National Key Research and Development Program of China ; National Key Research and Development Program of China ; Major Science and Technology Program of Anhui Province ; Major Science and Technology Program of Anhui Province ; Major Science and Technology Program of Anhui Province ; Major Science and Technology Program of Anhui Province ; Natural Science Foundation of Anhui Province ; Natural Science Foundation of Anhui Province ; Natural Science Foundation of Anhui Province ; Natural Science Foundation of Anhui Province ; Natural Science Foundation of the Anhui Higher Education Institutions of China ; Natural Science Foundation of the Anhui Higher Education Institutions of China ; Natural Science Foundation of the Anhui Higher Education Institutions of China ; Natural Science Foundation of the Anhui Higher Education Institutions of China ; Frontier Science Key Research Program of CAS ; Frontier Science Key Research Program of CAS ; Frontier Science Key Research Program of CAS ; Frontier Science Key Research Program of CAS ; National Natural Science Foundation of China ; National Natural Science Foundation of China ; National Natural Science Foundation of China ; National Natural Science Foundation of China ; National Key Research and Development Program of China ; National Key Research and Development Program of China ; National Key Research and Development Program of China ; National Key Research and Development Program of China ; Major Science and Technology Program of Anhui Province ; Major Science and Technology Program of Anhui Province ; Major Science and Technology Program of Anhui Province ; Major Science and Technology Program of Anhui Province ; Natural Science Foundation of Anhui Province ; Natural Science Foundation of Anhui Province ; Natural Science Foundation of Anhui Province ; Natural Science Foundation of Anhui Province ; Natural Science Foundation of the Anhui Higher Education Institutions of China ; Natural Science Foundation of the Anhui Higher Education Institutions of China ; Natural Science Foundation of the Anhui Higher Education Institutions of China ; Natural Science Foundation of the Anhui Higher Education Institutions of China ; Frontier Science Key Research Program of CAS ; Frontier Science Key Research Program of CAS ; Frontier Science Key Research Program of CAS ; Frontier Science Key Research Program of CAS
DOI10.1016/j.ejmech.2018.10.007
WOS KeywordBCR-ABL ; IMATINIB ; RESISTANCE ; MECHANISMS ; STRATEGIES ; BCR-ABL1 ; TUMORS ; DRUG
Indexed BySCI
Language英语
Funding ProjectNational Natural Science Foundation of China[81200371] ; National Natural Science Foundation of China[U1432250] ; National Natural Science Foundation of China[81471773] ; National Natural Science Foundation of China[81473088] ; National Natural Science Foundation of China[U1532154] ; National Natural Science Foundation of China[81703559] ; National Natural Science Foundation of China[21708044] ; National Key Research and Development Program of China[2016YFA0400900] ; Major Science and Technology Program of Anhui Province[16030801114] ; Major Science and Technology Program of Anhui Province[17030801025] ; Natural Science Foundation of Anhui Province[1708085MH208] ; Natural Science Foundation of Anhui Province[1808085MH274] ; Natural Science Foundation of Anhui Province[1208085QH154] ; Natural Science Foundation of Anhui Province[1708085MH224] ; Natural Science Foundation of the Anhui Higher Education Institutions of China[KJ2018ZD020] ; Frontier Science Key Research Program of CAS[QYZDB-SSW-SLH037]
Funding OrganizationNational Natural Science Foundation of China ; National Natural Science Foundation of China ; National Natural Science Foundation of China ; National Natural Science Foundation of China ; National Key Research and Development Program of China ; National Key Research and Development Program of China ; National Key Research and Development Program of China ; National Key Research and Development Program of China ; Major Science and Technology Program of Anhui Province ; Major Science and Technology Program of Anhui Province ; Major Science and Technology Program of Anhui Province ; Major Science and Technology Program of Anhui Province ; Natural Science Foundation of Anhui Province ; Natural Science Foundation of Anhui Province ; Natural Science Foundation of Anhui Province ; Natural Science Foundation of Anhui Province ; Natural Science Foundation of the Anhui Higher Education Institutions of China ; Natural Science Foundation of the Anhui Higher Education Institutions of China ; Natural Science Foundation of the Anhui Higher Education Institutions of China ; Natural Science Foundation of the Anhui Higher Education Institutions of China ; Frontier Science Key Research Program of CAS ; Frontier Science Key Research Program of CAS ; Frontier Science Key Research Program of CAS ; Frontier Science Key Research Program of CAS ; National Natural Science Foundation of China ; National Natural Science Foundation of China ; National Natural Science Foundation of China ; National Natural Science Foundation of China ; National Key Research and Development Program of China ; National Key Research and Development Program of China ; National Key Research and Development Program of China ; National Key Research and Development Program of China ; Major Science and Technology Program of Anhui Province ; Major Science and Technology Program of Anhui Province ; Major Science and Technology Program of Anhui Province ; Major Science and Technology Program of Anhui Province ; Natural Science Foundation of Anhui Province ; Natural Science Foundation of Anhui Province ; Natural Science Foundation of Anhui Province ; Natural Science Foundation of Anhui Province ; Natural Science Foundation of the Anhui Higher Education Institutions of China ; Natural Science Foundation of the Anhui Higher Education Institutions of China ; Natural Science Foundation of the Anhui Higher Education Institutions of China ; Natural Science Foundation of the Anhui Higher Education Institutions of China ; Frontier Science Key Research Program of CAS ; Frontier Science Key Research Program of CAS ; Frontier Science Key Research Program of CAS ; Frontier Science Key Research Program of CAS ; National Natural Science Foundation of China ; National Natural Science Foundation of China ; National Natural Science Foundation of China ; National Natural Science Foundation of China ; National Key Research and Development Program of China ; National Key Research and Development Program of China ; National Key Research and Development Program of China ; National Key Research and Development Program of China ; Major Science and Technology Program of Anhui Province ; Major Science and Technology Program of Anhui Province ; Major Science and Technology Program of Anhui Province ; Major Science and Technology Program of Anhui Province ; Natural Science Foundation of Anhui Province ; Natural Science Foundation of Anhui Province ; Natural Science Foundation of Anhui Province ; Natural Science Foundation of Anhui Province ; Natural Science Foundation of the Anhui Higher Education Institutions of China ; Natural Science Foundation of the Anhui Higher Education Institutions of China ; Natural Science Foundation of the Anhui Higher Education Institutions of China ; Natural Science Foundation of the Anhui Higher Education Institutions of China ; Frontier Science Key Research Program of CAS ; Frontier Science Key Research Program of CAS ; Frontier Science Key Research Program of CAS ; Frontier Science Key Research Program of CAS ; National Natural Science Foundation of China ; National Natural Science Foundation of China ; National Natural Science Foundation of China ; National Natural Science Foundation of China ; National Key Research and Development Program of China ; National Key Research and Development Program of China ; National Key Research and Development Program of China ; National Key Research and Development Program of China ; Major Science and Technology Program of Anhui Province ; Major Science and Technology Program of Anhui Province ; Major Science and Technology Program of Anhui Province ; Major Science and Technology Program of Anhui Province ; Natural Science Foundation of Anhui Province ; Natural Science Foundation of Anhui Province ; Natural Science Foundation of Anhui Province ; Natural Science Foundation of Anhui Province ; Natural Science Foundation of the Anhui Higher Education Institutions of China ; Natural Science Foundation of the Anhui Higher Education Institutions of China ; Natural Science Foundation of the Anhui Higher Education Institutions of China ; Natural Science Foundation of the Anhui Higher Education Institutions of China ; Frontier Science Key Research Program of CAS ; Frontier Science Key Research Program of CAS ; Frontier Science Key Research Program of CAS ; Frontier Science Key Research Program of CAS
WOS Research AreaPharmacology & Pharmacy
WOS SubjectChemistry, Medicinal
WOS IDWOS:000450383500006
PublisherELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
Citation statistics
Document Type期刊论文
Identifierhttp://ir.hfcas.ac.cn:8080/handle/334002/34323
Collection中科院强磁场科学中心
合肥创新院
Corresponding AuthorGe, Jian; Liu, Qingsong; Liu, Jing
Affiliation1.Chinese Acad Sci, Hefei Inst Phys Sci, Key Lab High Magnet Field & Ion Beam Phys Biol, High Field Magnet Lab, Hefei 230031, Anhui, Peoples R China
2.Univ Sci & Technol China, Hefei 230036, Anhui, Peoples R China
3.Chinese Acad Sci, Hefei Inst Phys Sci, Inst Technol Innovat, Precis Targeted Therapy Discovery Ctr, Hefei 230088, Anhui, Peoples R China
4.Precis Med Res Lab Anhui Prov, Hefei 230088, Anhui, Peoples R China
5.Anhui Med Univ, Affiliated Hosp 1, Dept Hematol, Hefei 230022, Anhui, Peoples R China
6.Anhui Univ, Inst Phys Sci & Informat Technol, Hefei 230601, Anhui, Peoples R China
Recommended Citation
GB/T 7714
Liu, Xuesong,Wang, Beilei,Chen, Cheng,et al. Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia[J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,2018,160:61-81.
APA Liu, Xuesong.,Wang, Beilei.,Chen, Cheng.,Jiang, Zongru.,Hu, Chen.,...&Liu, Jing.(2018).Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia.EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,160,61-81.
MLA Liu, Xuesong,et al."Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia".EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 160(2018):61-81.
Files in This Item:
File Name/Size DocType Version Access License
Discovery of (E)-N-((4593KB)期刊论文作者接受稿开放获取CC BY-NC-SAView Download
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Liu, Xuesong]'s Articles
[Wang, Beilei]'s Articles
[Chen, Cheng]'s Articles
Baidu academic
Similar articles in Baidu academic
[Liu, Xuesong]'s Articles
[Wang, Beilei]'s Articles
[Chen, Cheng]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Liu, Xuesong]'s Articles
[Wang, Beilei]'s Articles
[Chen, Cheng]'s Articles
Terms of Use
No data!
Social Bookmark/Share
File name: Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable.pdf
Format: Adobe PDF
This file does not support browsing at this time
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.